NCM · Financial Statements
Barinthus Biotherapeutics plc (BRNS) Financial Statements
$0.67
NCM: BRNS
Overview Financials Dividend Barinthus Biotherapeutics plc most recently reported annual revenue of $0, net profit of $-66.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2021 2022 2023 2024 2025 Revenue $0 $45.0M $1.0M $15.0M $0 Operating Profit $-45.0M $-4.0M $-84.0M $-68.0M $-71.0M Net Profit $-51.0M $5.0M $-73.0M $-61.0M $-66.0M EPS $-1.96 $0.14 $-1.91 $-1.55 $-1.64 Op Margin -16874.0% -9.0% -10463.0% -454.0% —
Balance Sheet (USD)
Metric 2021 2022 2023 2024 2025 Total Assets $281.0M $270.0M $215.0M $160.0M $98.0M Total Liabilities $28.0M $27.0M $28.0M $30.0M $24.0M Cash $214.0M $194.0M $142.0M $111.0M $70.0M Borrowings $0 $0 $0 $0 $0
Cash Flow (USD)
Metric 2021 2022 2023 2024 2025 Operating Cash Flow $-33.0M $-14.0M $-51.0M $-29.0M $-48.0M Investing Cash Flow $-13.0M $-6.0M $-5.0M $-1.0M $0 Financing Cash Flow $223.0M $0 $2.0M $2.0M $0 Net Cash Flow $177.0M $-20.0M $-54.0M $-28.0M $-48.0M Free Cash Flow $-34.0M $-21.0M $-56.0M $-30.0M $-48.0M
Valuation & Return Ratios
Metric Value PEG Ratio — EV / EBITDA — FCF Yield — Quick Ratio 7.80 Interest Coverage — Return 1Y -52.82% Return 3Y -70.35% Return 5Y —
Screens featuring this stock